Grekos Reports Successful Treatment of Heart Disease, Vascular Disease, Using Patients' Own Adult Stem Cells : Clinical Results
DUBAI, U.A.E. (Business Wire EON) November 19, 2008 -- "This is real science, real medicine and real results," Grekos stated. "We have moved beyond bench research and clinical trials to show that the power of the body's adult stem cells can be harnessed. Our success rate in reversing heart diseases like ischemic cardiomyopathy and congestive heart failure is extremely high. With our latest technology we're capturing the same astounding cell regeneration results in many other disease classifications."
Grekos, who is chief medical officer for Florida-based stem cell center Regenocyte Therapeutic, also announced that his team of physicians and scientists successfully treated a patient with Fabry disease - a previously untreatable enzyme deficiency which leads to heart and kidney failure. The patient's ejection fraction (EF) increased from 28 to 41 in just four months out from Adult Stem Cell Therapy (normal EF is 55.)
According to Dr. Grekos, "The patient no longer needs a heart transplant, which was previously the only means for arresting this disease. His kidney dialysis time has already been reduced by 10 percent, so we are looking at treating his kidney function in the near future."
Athina Kyritsis, MD and chair of Regenocyte's medical advisory committee, states, "As a physician I find one of the most exciting things this discovery offers is the potential to address many diseases currently believed to be untreatable. We are leaping off of medicine's cutting edge; this is no longer just theory."
The Stem Cell Treatment Process
Adult stem cells are extracted from a patient via a standard blood draw. This small, naturally occurring stem cell population is sent to a biotechnology laboratory where it is grown into millions of cells which are engineered to migrate to the part of the body needing repair. The patient receives the new cells one week later through an advanced injection and/or infusion delivery system. Unlike surgically implanted devices, medications, or organ replacement surgery, using a patient's own stem cells to rebuild damaged tissue means there is no possibility of rejection or tumorgenicity (cancer causing).
About the Physician
Zannos Grekos, MD is an interventional cardiologist based in Florida. He is chief medical officer for Regenocyte Therapeutic, one of the world's first clinically treating adult stem cell centers. He is associate clinical professor of Cardiology for Nova Southeastern University and has been appointed to the Science Advisory Board of Washington, D.C.'s Repair Stem Cell Institute. In February 2007, he was invited to brief the United States Senate Health Advisory Staff on the current state of stem cell research and stem cell therapy.
Regenocyte Therapeutic is currently using Adult Stem Cell Therapy to treat Congestive Heart Failure, Cardiomyopathy, Peripheral Artery Disease, Coronary Artery Disease, Kidney Disease, Ischemic Heart Disease, Pulmonary Disease and Early Senile Dementia. Patients can call 866-216-5710 for information or consultation.
Related Themes:
Related Websites
Know your heart and its disease.
There are a variety of ailments related to the heart and providing information on all the types of cardio vascular disease could be quite a task. Yet a look at conditions that affect the heart and blood vessels can give you a broad view of cardiovascular disease.
M2S to Sponsor Dinner Symposium on Vascular Quality Improvement Registries at Vascular Annual Meeting
M2S Inc., a Clinical Technology Organization and industry leader in endovascular treatment planning and patient data registries, announced today that the company will sponsor a dinner symposium titled "Vascular Quality Improvement Registries" at the 2009 Vascular Annual Meeting on June 12, 2009 in Denver, Colorado. The symposium will demonstrate how participation in a multi-center cooperative patient data registry can improve vascular healthcare, highlighting the six-year experience of the Vascular Study Group of Northern New England (VSGNNE). Participants will learn what to expect from, and how to set up, their own regional registries.
African-American Heart Attack Survivors Cite Experience as a "Wake-Up Call" to Address Health and Life Issues
National Medical Association Survey of Heart Attack Survivors uncovers emotional impact, educational needs and disparity among racial groups.
The Fastest Cardio Workouts Ever
Cardio workout is a form of exercise that raises your heart rate to a level higher than its maximum rate and sustaining that rate for a period of time There are various types of cardio exercises but they can narrowed down into two main types: the Low-Intensity Cardio and High-Intensity Cardio Workout
Vascular BioSciences Extends Patent Portfolio: Signs Exclusive IP License Agreement with The Burnham Institute for Medical Research
Vascular BioSciences announced today that it has secured a worldwide exclusive license to intellectual property from Burnham Institute for Medical Research relating to work done by Erkki Ruoslahti M.D Ph.D., and Masanobu Komatsu, Ph.D. on their discovery of the role of the intracellular protein R-Ras in neointimal hyperplasia, angiogenesis and vascular proliferation. Drs. Komatsu and Ruoslahti found that R-Ras exerts a strong inhibitory effect on mitotic and invasive activities of activated endothelial cells and vascular smooth muscle cells, and promotes quiescence of these cells.
M2S, Inc. Makes Contribution to American Vascular Association
M2S, Inc., a global provider of image management services for endovascular imaging and medical device clinical trials, announced that it has made a contribution to the Open the Pathway campaign of the American Vascular Association (AVA). Open the Pathway is an initiative that was established to improve vascular health. M2S has a long-term commitment to vascular treatment planning, post-operative patient outcomes and medical data registries. With their contribution, M2S will hold a seat on the Industry Advisory Council, where members of the vascular medicine community come together to discuss critical topics facing the industry.
Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner
The Vascular Disease Foundation has a new partner and sponsor in Life Line Screening. The two companies aim to further educate the population about vascular disease and vascular testing services like abdominal aortic aneurysm (http://www.lifelinescreening.com/health-screening-services/abdominal-aortic-aneurysm.aspx) and peripheral arterial disease screening (http://www.lifelinescreening.com/health-screening-services/peripheral-arterial-disease.aspx). Life Line Screening will distribute the foundation’s educational publications and provide online registration so that its customers can easily donate money to the foundation. ...
